Evaxion A/S business relationships
Companies named in Evaxion A/S’s 20-F filed 2026-03-05, and public companies whose annual reports name Evaxion A/S. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 73 / 100 Top 2% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 10 / 100
Named in Evaxion A/S’s annual report 4
“In September 2025, the Company out-licensed its vaccine candidate EVX- B3 to MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) as per the option and license agreement entered between the two companies in September 2024.” SEC filing
“We have in the period ended December 31, 2025, generated revenues $7.5 million primarily from our license agreement with Merck Sharpe Dome (MSD).” SEC filing
“Our operations have been funded primarily through equity financings, convertible debt, and private and governmental grants, and, most recently our partnership with Merck.” SEC filing
“...Agreement by and among Evaxion Biotech A/S, MSD International GmbH and MSD International Business GmbH, subsidiaries of Merck & Co., Inc., (known collectively as MSD outside the United States and Canada) (Incorporate by Reference to Exhibit 99.2 to Form 6-K filed with the Commission on October 25, 2...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.